Boston Scientific (BSX) PT Raised to $64 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $46.02 +5.79%
Rating Summary:
28 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
28 Buy, 14 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst William Plovanic raised the price target on Boston Scientific (NYSE: BSX) to $64.00 (from $60.00) while maintaining a Buy rating.
You May Also Be Interested In
- Increasing unusual call option volume: BSX SGHC USAS SYF INO CHGG EVGO REAL ITB MNRO KMX MSOS SGI PGY HNST GMAB
- Livanova (LIVN) PT Raised to $115 at Mizuho
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
